{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT06393374","nct_id":"NCT06393374","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06393374. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab every 6 weeks (q6w) in combination with sacituzumab tirumotecan every 2 weeks (q2w) for 24 weeks. In addition, participants receive an antihistamine, an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to sacituzumab tirumotecan infusions.","label":"Pembrolizumab + sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"Participants receive pembrolizumab q6w or pembrolizumab q6w in combination with capecitabine (twice daily \\[BID\\] on Days 1 to 14 and 22 to 35 every 42 days x 4 \\[2 weeks 1, 1 week off\\]) for 24 weeks.","label":"Treatment of Physician's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2037-12-14","type":"ESTIMATED"},"conditions":["Triple-Negative Breast Cancer"],"enrollment":{"count":1530,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["KEYTRUDA®","MK-3475","SCH 900475"],"type":"BIOLOGICAL"},{"name":"Sacituzumab tirumotecan","otherNames":["MK-2870"],"type":"BIOLOGICAL"},{"name":"Capecitabine","otherNames":["XELODA"],"type":"DRUG"}],"last_update":"2026-11-18","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-12-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Invasive Disease-Free Survival (iDFS)","timeFrame":"Up to approximately 77 months"}],"references":[],"start_date":{"date":"2024-06-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","url":"https://clinicaltrials.gov/study/NCT06393374"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06393374"}